Today’s PR shows me that the company continues to march forward. DECN has several products in its bag...GenUltimate, GenSure, GenChoice and GenPrecise. Some are developed and for sale, and some are being developed. The ultimate product still in development, GenPrecis, is considered the silver bullet. These products don’t get designed, tested and approved for sale over night, but I like the path that DECN is on. Additionally, the private label strategy is in the works and hopefully, news on that front is right around the corner.
In my opinion, the strategy of continuing to develop accurate, affordable products can only help their case against J&J. Also, it proves that without J&J bogging them down in past legal activities they would be much further along as a medical device/manufacturing company right now.
The Chinese company that is potentially looking into buying J&J’s diabetes business may also be looking at what DECN is doing from a product development standpoint as well as how DECN and J&J are entangled in a legal battle.
Just some thoughts, in my opinion, of course.
(2)
(0)
Decision Diagnostics Corp (DECN) Stock Research Links